Mostrar el registro sencillo del ítem

Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus

dc.rights.licenseopenen_US
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorGENSOUS, Noemie
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorLAZARO, Estibaliz
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorBLANCO, Patrick
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorRICHEZ, Christophe
dc.date.accessioned2024-11-14T15:16:45Z
dc.date.available2024-11-14T15:16:45Z
dc.date.issued2024
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/203284
dc.description.abstractEnType 1 interferons (IFNs) play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE) and various type I IFNs targeting therapeutic approaches have been developed. Anifrolumab, a monoclonal antibody that binds to the subunit 1 of the type I IFN receptor, has acquired considerable interest and has entered different clinical human trials willing to evaluate its efficacy and safety. Areas covered: This review summarizes the data obtained in phases 1, 2, and 3 clinical trials of anifrolumab for SLE patients. A focus is made on data of clinical efficacy and safety obtained in MUSE, TULIP-1 and TULIP-2 trials. Expert opinion/Commentary: Anifrolumab is a promising therapeutic option for patients with SLE, currently authorized for moderate-to-severe SLE. Extensive real-world use is now going to generate data required to gain experience on the type of patients who benefit the most from the drug, and the exact positioning of anifrolumab in the therapeutic plan.
dc.language.isoENen_US
dc.subject.enAnifrolumab
dc.subject.enCOVID-19
dc.subject.enBiologics
dc.subject.enCutaneous lupus erythematosus
dc.subject.enHerpes zoster
dc.subject.enSystemic lupus erythematosus
dc.subject.enType I interferons
dc.title.enAnifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/1744666X.2023.2268284en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
dc.identifier.pubmed37800604en_US
bordeaux.journalExpert Review of Clinical Immunologyen_US
bordeaux.page21 – 30en_US
bordeaux.volume20en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04783525
hal.version1
hal.date.transferred2024-11-14T15:16:47Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Expert%20Review%20of%20Clinical%20Immunology&rft.date=2024&rft.volume=20&rft.issue=1&rft.spage=21%20%E2%80%93%2030&rft.epage=21%20%E2%80%93%2030&rft.au=GENSOUS,%20Noemie&LAZARO,%20Estibaliz&BLANCO,%20Patrick&RICHEZ,%20Christophe&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem